Drug Profile
Relamorelin - AbbVie
Alternative Names: BIM-28131; BIM-28163; RM 131Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ipsen
- Developer AbbVie; Ipsen
- Class Gastrokinetics; Growth hormone-releasing hormones; Peptides; Piperidines; Thiophenes
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cachexia; Constipation; Diabetic gastroparesis; Gastrointestinal disorders
Most Recent Events
- 08 Oct 2020 Allergan terminates a phase IIIb trial for diabetic gastroparesis in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, France, Germany, Hungary, India, Israel, Italy, South Korea, Latvia, Malaysia, Mexico, Philippines, Poland, Romania, Russia, Singapore, South Africa, Spain, Thailand, Ukraine, United Kingdom and USA (SC) (NCT03786380) (EudraCT2019-000406-30)
- 30 Sep 2020 Allergan terminates a phase III trial for Diabetic gastroparesis in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, , France, Germany, Hungary, India, Israel, Italy, Latvia, Malaysia, Mexico, Philippines, Poland, Romania, Russia, Saudi Arabia, Scotland, Singapore, South Africa, South Korea, Spain, Taiwan, Thailand, Ukraine, United Arab Emirates, United Kingdom (SC) (NCT03383146)
- 30 Sep 2020 Allergan terminates a phase III trial for diabetic gastroparesis in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Denmark, England, France, Germany, Hungary, India, Israel, Italy, Latvia, Malaysia, Mexico, Multinational, Philippines, Poland, Puerto Rico, Romania, Russia, Saudi Arabia, Scotland, Serbia, Singapore, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom (SC) (NCT03420781)